ABACUS BIOSCIENCE INC
Immunotherapeutic platform technology that targets tumor-associated antigens to CD180-activated immune cells to overcome checkpoint inhibitor resistance in cancer and chronic infectious diseases
- Sector
- Biotech
- Headquarters
- Sammamish, WA
- Latest Form D
- $4.4M, Feb 2023
- Total capital
- $4.8M
- Federal grants
- $398K
- 1 award · 2022
- Rank in peer group#370 of 502
- Private capital raised
- $4.4M
- 1 Form D · last Feb 2023
- 45 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- first 2024
- Rank in peer group#28 of 502
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.4M
- Federal grantHealth and Human S · Phase I · Development of Novel CD180-Based Cancer Immunotherapeutics$398K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
8months
from ABACUS BIOSCIENCE INC’s first federal award to its first private round.
- First federal award · Jun 2022
- Health and Human S · $398K
- First Form D · Feb 2023
- $4.4M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#28 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan WahlExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Che-Leung LawDirectorNamed in SEC Form D filings
- Diane HollenbaughDirectorNamed in SEC Form D filings
- Jonathan DrachmanDirectorNamed in SEC Form D filings
- Will CanesteroDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 3- GrantedTherapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core AntigenUSPTOUS 12,496,339
- GrantedTherapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope proteinUSPTOUS 12,285,482
- GrantedTherapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core AntigenUSPTOUS 11,883,488
Related companies, and why
- ARMONICA TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- Oncoimmune IncSimilar federal contract value in Biotech · null in contracts
- GLOBIN SOLUTIONS INCSimilar federal contract value in Biotech · null in contracts
- BIOATLA, LLCSimilar federal contract value in Biotech · null in contracts
- TAMUROBIO INC.Similar federal contract value in Biotech · null in contracts
- MUSTANG BIO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .